Outcomes in older adults with acute lymphoblastic leukaemia (ALL): results from the international MRC UKALL XII/ECOG2993 trial.
about
New and emerging prognostic and predictive genetic biomarkers in B-cell precursor acute lymphoblastic leukemiaPotential for bispecific T-cell engagers: role of blinatumomab in acute lymphoblastic leukemiaMonoclonal antibodies in acute lymphoblastic leukemiaPegylated-asparaginase during induction therapy for adult acute lymphoblastic leukaemia: toxicity data from the UKALL14 trialPneumonia during remission induction chemotherapy in patients with acute leukemia.Unmanipulated haploidentical stem cell transplantation in adults with acute lymphoblastic leukemia: a study on behalf of the Acute Leukemia Working Party of the EBMT.Efficacy of CPX-351, (cytarabine:daunorubicin) liposome injection, against acute lymphoblastic leukemia (ALL) xenograft models of the Pediatric Preclinical Testing ProgramOutcome of Adolescents with Acute Lymphoblastic Leukemia Treated by Pediatrics versus Adults ProtocolsReceipt of maintenance therapy is most predictive of survival in older acute lymphoblastic leukemia patients treated with intensive induction chemotherapy regimens.High incidence of Philadelphia chromosome-like acute lymphoblastic leukemia in older adults with B-ALL.Acute lymphoblastic leukemia in adults: encouraging developments on the way to higher cure rates.Pharmacokinetically-targeted BU and fludarabine as conditioning before allogeneic hematopoietic cell transplantation for adults with ALL in first remission.Phase 2 study of intensified chemotherapy and allogeneic hematopoietic stem cell transplantation for older patients with acute lymphoblastic leukemia.A Phase 2 study of L-asparaginase encapsulated in erythrocytes in elderly patients with Philadelphia chromosome negative acute lymphoblastic leukemia: The GRASPALL/GRAALL-SA2-2008 study.New insights into the pathophysiology and therapy of adult acute lymphoblastic leukemia.The evolving role of chemotherapy and hematopoietic cell transplants in Ph-positive acute lymphoblastic leukemia in adults.Tyrosine kinase inhibitors in Ph+ acute lymphoblastic leukaemia: facts and perspectives.Minimal Residual Disease in Acute Lymphoblastic Leukemia: How to Recognize and Treat It.Advances in adult acute lymphoblastic leukemia therapy.Acute lymphoblastic leukemia: an assessment of international incidence, survival, and disease burden.Allogeneic transplantation is not superior to chemotherapy in most patients over 40 years of age with Philadelphia-negative acute lymphoblastic leukemia in first remission.Prognostic impact of persistent cytogenetic abnormalities at complete remission in adult patients with acute lymphoblastic leukemia.Improved survival in adult patients with acute lymphoblastic leukemia in the Netherlands: a population-based study on treatment, trial participation and survival.Potent efficacy of combined PI3K/mTOR and JAK or ABL inhibition in murine xenograft models of Ph-like acute lymphoblastic leukemia.Treatment of elderly patients with acute lymphoblastic leukaemia using a paediatric-based protocol.Prognostic significance of day 14 bone marrow evaluation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia.Prognostic impact of pretreatment cytogenetics in adult Philadelphia chromosome-negative acute lymphoblastic leukemia in the era of minimal residual disease.Rituximab in the management of acute lymphoblastic leukemia.Incidence, socioeconomic deprivation, volume-outcome and survival in adult patients with acute lymphoblastic leukaemia in England.Current challenges and opportunities in treating adult patients with Philadelphia-negative acute lymphoblastic leukaemia.Treatment of Older Patients with Acute Lymphoblastic Leukaemia.Overall survival among older US adults with ALL remains low despite modest improvement since 1980: SEER analysis.A pilot study of daunorubicin-augmented hyper-CVAD induction chemotherapy for adults with acute lymphoblastic leukemia.Allogeneic stem cell transplantation in acute lymphoblastic leukemia patients older than 60 years: a survey from the acute leukemia working party of EBMT.An antithrombin replacement strategy during asparaginase therapy for acute lymphoblastic leukemia is associated with a reduction in thrombotic events.BCL2 inhibitor ABT-199 and JNK inhibitor SP600125 exhibit synergistic cytotoxicity against imatinib-resistant Ph+ ALL cellsManagement of older adults with acute lymphoblastic leukemia: challenges & current approaches
P2860
Q26749177-1957EB85-4068-4034-ACFA-F8B3E734FFD0Q26764903-35B360FA-5A0D-4177-93FF-16DC6D591860Q27022540-0DD66948-47EE-4286-89A0-09BE4AC42412Q31118945-DA2A64A6-7510-426B-AE21-FE301376DFF3Q33410062-70C0290F-C1CC-46C4-8D34-7260FCE3AE25Q33742940-42E8E413-417F-4619-BD0C-2DB572705020Q34543909-3C998401-84F7-4653-BFB4-37484F75C166Q34610024-8F5694FD-D4EA-454C-9550-B50931FF6B55Q34703903-C7F5A043-E9CA-47D9-B608-C101DE7DCA17Q37739018-5233A3A0-8600-40FC-BFF3-268BDD224F96Q38095113-60FF96F9-96D0-42FA-9427-42A0F81056B0Q38133244-A250E4C6-FEEC-47AF-A300-DA4BAC0E9706Q38392656-74401492-FC25-46AB-8E7B-E720E51F8FEAQ38409519-76FA4BEA-79A3-4210-8265-85E5953B9A2FQ38428357-EF9E0A1F-1E8B-48CD-969F-FBF615F274D6Q38674733-B923C290-7FB3-4565-8C65-F366408051AAQ38739574-8AE0D29A-A27D-4C60-9E01-3D7895517396Q38756821-149246B5-B5AA-4F61-B6F7-837B7FFE560AQ39459190-2BF7375E-26D4-401D-B989-6633CA717F2BQ40532933-95621402-B99D-4CF1-946C-E0C3C61785F0Q40765997-F64B312A-62B9-49C3-A602-72079658ADF5Q40957292-6645D4B2-4859-4740-9512-A486BCEC8795Q41472241-895166ED-8662-42FA-A7C1-3D80654B6575Q44018556-38B8D7E0-4983-47AC-B666-1F2E661E6D10Q45395583-8375F1FF-A94E-4A53-924C-623568C00657Q46176860-EB8F1710-2F79-47B1-B48F-512B2B1CBA5EQ46477192-862FC5CB-42E5-4DE5-8AE2-D9616895A4F6Q47196522-7FFB0F75-D86C-44EE-8D8E-25C56D7A2B45Q47208658-E5A93F3A-4261-40DE-AFEF-15D0447CE1F1Q47706549-8F39DBDA-38F2-4F79-910C-CAFBD4FD113FQ47774455-BB40D80A-8691-41EE-BC01-BB9D329E0264Q48311791-054E5955-701A-4D8A-A78A-564487CAD400Q48320885-B09BBE0E-7DDB-4E66-837C-678495D65AFEQ49165760-7E1FAF6E-EAE8-40F0-A7E4-88DF4E0D40B5Q50861405-6686E2E8-BF67-48EB-96A1-1204BFD8D0BFQ57176106-3E71F203-FA96-4E5E-87CB-E91CBE2BD08CQ57301411-3329545F-5E6C-49A0-8E8B-C68DEDADB81B
P2860
Outcomes in older adults with acute lymphoblastic leukaemia (ALL): results from the international MRC UKALL XII/ECOG2993 trial.
description
2012 nî lūn-bûn
@nan
2012 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի մարտին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
name
Outcomes in older adults with ...... MRC UKALL XII/ECOG2993 trial.
@ast
Outcomes in older adults with ...... MRC UKALL XII/ECOG2993 trial.
@en
Outcomes in older adults with acute lymphoblastic leukaemia
@nl
type
label
Outcomes in older adults with ...... MRC UKALL XII/ECOG2993 trial.
@ast
Outcomes in older adults with ...... MRC UKALL XII/ECOG2993 trial.
@en
Outcomes in older adults with acute lymphoblastic leukaemia
@nl
prefLabel
Outcomes in older adults with ...... MRC UKALL XII/ECOG2993 trial.
@ast
Outcomes in older adults with ...... MRC UKALL XII/ECOG2993 trial.
@en
Outcomes in older adults with acute lymphoblastic leukaemia
@nl
P2093
P2860
P1476
Outcomes in older adults with ...... MRC UKALL XII/ECOG2993 trial.
@en
P2093
Adele Fielding
Andrew McMillan
Anthony H Goldstone
Anthony V Moorman
David I Marks
Georgina Buck
Jacob M Rowe
Jonathan I Sive
Mark R Litzow
Selina Luger
P2860
P304
P356
10.1111/J.1365-2141.2012.09095.X
P407
P577
2012-03-13T00:00:00Z